Voelcker Academy

Research Symposium 2009

 

previous next
 
Kael Mcinnis

Intranasal Delivery of Erythropoietin plus Insulin-Like Growth Factor I for Acute Neuroprotection in Stroke

Kael Mcinnis

Mentor(s): L. Fletcher, S. Kohli, S. Sprague, S. Scranton, A. Parra, D. F. Jimenez, Murat Digicaylioglu

Stroke is the third most common cause of death in the United States. The blood-brain barrier (BBB) restricts the delivery of a wide range of possible therapeutic agents for stroke patients. Intranasal (i.n.) drug administration is a non-invasive method that circumvents the BBB and provides rapid drug absorption without systemic side effects. Erythropoietin (EPO) and insulin-like growth factor-I (IGF-I) significantly reduce neuronal damage in rodent models of stroke. The aim of this study was to determine that intranasal EPO + IGF-I can improve neurological outcomes in an animal stroke model and establish intranasal administration as an efficient drug delivery method for EPO + IGF-I.